Suppr超能文献

胰岛素生长因子抑制剂作为一种潜在的新型抗血吸虫药物:体内实验研究。

Insulin growth factor inhibitor as a potential new anti-schistosoma drug: An in vivo experimental study.

机构信息

Department of Medical Parasitology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

出版信息

Biomed Pharmacother. 2017 Nov;95:1346-1358. doi: 10.1016/j.biopha.2017.09.015. Epub 2017 Sep 19.

Abstract

BACKGROUND AND OBJECTIVE

Tyrphostin "AG1024" is an insulin growth factor-1 receptor (IGF-1R) inhibitor that displayed an effect on the viability of larval and mature schistosomes in vitro. We sought to investigate the possible in vivo role of AG1024 as a potential new anti-Schistosoma drug against immature and adult stages of Schistosoma mansoni and its effect on the degree of hepatic fibrosis and insulin pathway.

METHODS

The study included a control non-infected group and 5 groups of S. manosoni-infected CD-1 albino mice (20 mice each) assigned to treatment as follows: vehicle-treated, early AG1024, 30μg/100μl DMSO, IP for 10days started 30days post-infection (dpi), early praziquantel (PZQ), 500mg/kg orally for 2days (30dpi), late AG1024 (60dpi), and late PZQ (60dpi). All mice were sacrificed 12 weeks post-infection. Parasitological, chemical and histopathological parameters were studied. Immunohistochemistry of TGF-β and GLUT4 in liver sections was done to further evaluate the effect of AG1024 on the degree of hepatic fibrosis and insulin signaling pathway, respectively.

RESULTS

Early administration of AG1024 (30dpi) resulted in significant reduction of hepatic and intestinal tissue egg count with a reduction of 79.99% and 89.1% respectively. Late administration of AG1024 (60dpi) led to 77.78% reduction of intestinal eggs count; however, hepatic egg count wasn't reduced significantly. No reduction in worm burden was recorded for both administration regimens. Both regimens lead to significant decrease of both ALT and AST, mean hepatic granuloma diameter but an increase in fibrosis percentage (65.2% and 55% respectively). Both early and late treatment with AG1024 showed a significant increment of TGF-β expression by 71.4% and 39.3%, respectively (p<0.0001) compared to PZQ-treated and infected non-treated groups. Hepatic GLUT4 expression was significantly decreased compared to infected non-treated group (p<0.001) and the corresponding PZQ-treated group.

CONCLUSION

Early AG1024 administration induced more significant results compared to early PZQ with a promising activity against egg production and subsequent reduction of tissue egg load rather than direct schistosomicidal effect; however, it induced granuloma fibrosis, TGF-β expression, and disrupted the insulin signaling pathway.

摘要

背景与目的

Tyrphostin“AG1024”是一种胰岛素样生长因子-1 受体(IGF-1R)抑制剂,在体外对幼虫和成熟血吸虫的活力有作用。我们试图研究 AG1024 作为一种新的抗血吸虫潜在药物在曼氏血吸虫未成熟和成虫阶段的可能体内作用,及其对肝纤维化和胰岛素通路程度的影响。

方法

该研究包括一个非感染对照组和 5 组感染 CD-1 白化病小鼠(每组 20 只),分别给予以下治疗:载体处理、早期 AG1024、30μg/100μl DMSO,IP 治疗,从感染后 30 天(dpi)开始 10 天(早期)、早期吡喹酮(PZQ)、500mg/kg 口服,2 天(30dpi)、晚期 AG1024(60dpi)和晚期 PZQ(60dpi)。所有小鼠在感染后 12 周被处死。研究了寄生虫学、化学和组织病理学参数。对肝组织切片中的 TGF-β和 GLUT4 进行免疫组织化学染色,以进一步评估 AG1024 对肝纤维化和胰岛素信号通路程度的影响。

结果

早期给予 AG1024(30dpi)可显著减少肝和肠道组织中的虫卵计数,分别减少 79.99%和 89.1%。晚期给予 AG1024(60dpi)可使肠道虫卵计数减少 77.78%;然而,肝内虫卵计数无显著减少。两种给药方案均未记录到虫体负荷减少。两种方案均显著降低 ALT 和 AST,平均肝肉芽肿直径,但增加纤维化百分比(分别为 65.2%和 55%)。与吡喹酮治疗和未感染对照组相比,早期和晚期使用 AG1024 治疗均使 TGF-β表达增加 71.4%和 39.3%(p<0.0001)。与未感染对照组相比,肝 GLUT4 表达显著降低(p<0.001),与相应的吡喹酮治疗组相比也是如此。

结论

与早期吡喹酮相比,早期 AG1024 给药诱导的结果更显著,对产卵有潜在的活性,并随后减少组织内虫卵负荷,而不是直接杀血吸虫作用;然而,它诱导肉芽肿纤维化、TGF-β表达,并破坏胰岛素信号通路。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验